IP Library Granted Patent US 8,097,266
Granted Patent B2
US 8,097,266 · App. 12/324,066 · Granted Jan 17, 2012

Solvent systems for pour-on formulations for combating parasites

Assignee: Merial Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,097,266
App. No.
12/324,066
Granted
Jan 17, 2012
Kind
B2
Abstract

This invention relates to pharmaceutical and veterinary formulations providing enhanced solvency and stability for pharmaceutical and veterinary agents for administration to animals, especially ruminants. In addition, the invention relates to pour-on formulations for combating parasites in animals, such as cattle and sheep. In some embodiments, this invention provides glycol-ether-based pour-on formulations comprising a composition comprising a flukicide, such as, for example, clorsulon (4-amino-6-trichloroethenyl-1,3-benzene disulfonamide) and/or a macrolide anthelmintic or antiparasitic agent. In other embodiments, the invention provides pour-on formulations comprising at least one active agent, a glycol ether, and a stability enhancer. This invention also provides for methods for eradicating, controlling, and/or preventing parasite infestation in animals, such as cattle and sheep.

Claims (16)

1. A stable veterinary formulation for topical, transdermal treatment or prophylaxis of a parasitic infection or infestation in an animal, comprising:

(a) about 8% to about 12% (w/v) clorsulon;

(b) about 0.3% to about 2% (w/v) eprinomectin;

(c) about 40% to about 60% diethylene glycol monoethyl ether;

(d) about 5% glycerol formal;

(e) about 20% to about 50% (w/v) propylene glycol diesters of caprylic and capric acids; and

(f) from zero to about 0.1% (w/v) butylated hydroxy toluene.

2. The formulation of claim 1 comprising:

(a) about 10% (w/v) clorsulon;

(b) about 0.5% (w/v) or about 1.0% (w/v) eprinomectin;

(c) about 40% or about 58% diethylene glycol monoethyl ether;

(d) about 5% glycerol formal;

(e) about 25% or about 43% (w/v) propylene glycol diesters of caprylic and capric acids; and

(f) about 0.05% (w/v) butylated hydroxy toluene.

3. The formulation of claim 1 or 2 wherein the stability of the macrocyclic lactone active agent is enhanced in that less than 20% by weight of macrocyclic lactone degradation is demonstrated when the formulation is stored at 50° C. for three months.

4. A method of treating or preventing parasitic infection in an animal, comprising topically administering the formulation of claim 1 , 2 , or 3 to the animal.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2015
From: MERIAL LIMITED
To: MERIAL, INC.
Reel/Frame 035576/0042 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2009
From: GOGOLEWSKI, RONALD PETER; CLEVERLY, DOUGLAS; THWAITES, PAUL; SOLL, MARK DAVID
To: MERIAL LIMITED
Reel/Frame 023523/0755 →
Continuity (2)
Provisional Application 60990205 · Nov 26, 2007
Related Publication 20090163575A1 · Jun 25, 2009